The Role of PSMA PET Imaging in the Classification of the Risk of Prostate Cancer Patients: A Systematic Review on the Insights to Guide an Active Surveillance Approach

被引:0
|
作者
Dondi, Francesco [1 ,2 ]
Antonelli, Alessandro [3 ]
Suardi, Nazareno [4 ]
Treglia, Giorgio [5 ,6 ,7 ]
Bertagna, Francesco [1 ,2 ]
机构
[1] ASST Spedali Civili Brescia, Nucl Med, I-25123 Brescia, Italy
[2] Univ Brescia, I-25123 Brescia, Italy
[3] Univ Verona, Dept Urol, Azienda Osped Univ Integrata Verona, I-37134 Verona, Italy
[4] Spedali Civili Brescia, Dept Urol, I-25123 Brescia, Italy
[5] Ente Osped Cantonale, Imaging Inst Southern Switzerland, Nucl Med, CH-6500 Bellinzona, Switzerland
[6] Univ Lausanne, Lausanne Univ Hosp, Dept Nucl Med & Mol Imaging, CH-1011 Lausanne, Switzerland
[7] Univ Svizzera Italiana, Fac Biomed Sci, CH-6900 Lugano, Switzerland
关键词
PSMA; prostate-specific membrane antigen; positron emission tomography; PET; prostate cancer; active surveillance; nuclear medicine; RADICAL PROSTATECTOMY; INTERMEDIATE; ANTIGEN;
D O I
10.3390/cancers16061122
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The prognosis of prostate cancer (PCa) patients and their best therapeutic approach are related to the risk-based classification of this neoplasm since subjects with higher risk could have a higher incidence of recurrence. In addition, patients with low- and intermediate-risk PCa could benefit from active surveillance (AS). Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging has demonstrated its value for the assessment, prognostic role, and ability to guide the therapy of PCa. The aim of this systematic review was to assess the role of PSMA PET in guiding the correct classification of low-to-intermediate risk PCa subjects and the AS approach. Insights on the value of this imaging modality in these settings have emerged; however, further research in this field is necessary to clearly define the role of PSMA PET.Abstract Background: active surveillance (AS) is a suitable strategy for patients with prostate cancer (PCa). Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging is an established tool used to assess PCa. The aim of this review was to evaluate the role of PSMA imaging to guide correct risk-based classification and the AS approach in PCa patients. Methods: The Scopus, Embase, Web of Science, Cochrane Library, and PubMed/MEDLINE databases were screened to find relevant published articles. Results: 1774 articles were revealed with the literature search. A total of 1764 articles were excluded after applying exclusion criteria (data not within the field of interest, preclinical papers, conference proceedings, reviews, or editorials). Ten studies were finally included in the review, revealing that PSMA PET could have the ability to guide risk-based classification of PCa and the choice of AS, and to guide the execution of biopsies for the research of high-grade PCa, therefore precluding AS. Conclusion: this systematic review underlined a possible role of PSMA PET imaging in patients with PCa by correctly re-classifying them on the basis of their risk and guiding AS.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Active surveillance for clinically localized prostate cancer--A systematic review
    Thomsen, Frederik B.
    Brasso, Klaus
    Klotz, Laurence H.
    Roder, M. Andreas
    Berg, Kasper D.
    Iversen, Peter
    JOURNAL OF SURGICAL ONCOLOGY, 2014, 109 (08) : 830 - 835
  • [2] Role of PSMA PET/CT in imaging and management of prostate cancer
    El Hoyek, Nadine
    Shi, Xiaolei
    Jenkins, Jason
    Chen, Wengen
    CURRENT OPINION IN ONCOLOGY, 2025, 37 (03) : 233 - 239
  • [3] Current role of PSMA-PET imaging in the clinical management of prostate cancer
    Georgakopoulos, Alexander
    Bamias, Aristotle
    Chatziioannou, Sophia
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [4] The role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer
    Bagguley, Dominic
    Ong, Sean
    Buteau, James P.
    Koschel, Sam
    Dhiantravan, Nattakorn
    Hofman, Michael S.
    Emmett, Louise
    Murphy, Declan G.
    Lawrentschuk, Nathan
    FUTURE ONCOLOGY, 2021, 17 (17) : 2225 - 2241
  • [5] The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels
    Kabasakal, Levent
    Demirci, Emre
    Nematyazar, Jamal
    Akyel, Resit
    Razavi, Baresh
    Ocak, Meltem
    Aygun, Aslan
    Obek, Can
    Kural, Ali R.
    NUCLEAR MEDICINE COMMUNICATIONS, 2017, 38 (02) : 149 - 155
  • [6] The role of diagnostic ultrasound imaging for patients with known prostate cancer within an active surveillance pathway: A systematic review
    Parker, Pamela
    Twiddy, Maureen
    Whybrow, Paul
    Rigby, Alan
    Simms, Matthew
    ULTRASOUND, 2022, 30 (01) : 4 - 17
  • [7] Is There a Role for Active Surveillance in Low-Risk Prostate Cancer?
    Augustin, Herbert
    Mayerhofer, Katrin
    Seles, Maximilian
    Pummer, Karl
    UROLOGIA INTERNATIONALIS, 2015, 95 (02) : 125 - 131
  • [8] Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review
    Manceau, Cecile
    Fromont, Gaelle
    Beauval, Jean-Baptiste
    Barret, Eric
    Brureau, Laurent
    Crehange, Gilles
    Dariane, Charles
    Fiard, Gaelle
    Gauthe, Mathieu
    Mathieu, Romain
    Renard-Penna, Raphaele
    Roubaud, Guilhem
    Ruffion, Alain
    Sargos, Paul
    Roupret, Morgan
    Ploussard, Guillaume
    CANCERS, 2021, 13 (17)
  • [9] A Systematic Approach to Discussing Active Surveillance with Patients with Low-risk Prostate Cancer
    Ehdaie, Behfar
    Assel, Melissa
    Benfante, Nicole
    Malhotra, Deepak
    Vickers, Andrew
    EUROPEAN UROLOGY, 2017, 71 (06) : 866 - 871
  • [10] Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: A Systematic Review
    Schoots, Ivo G.
    Petrides, Neophytos
    Giganti, Francesco
    Bokhorst, Leonard P.
    Rannikko, Antti
    Klotz, Laurence
    Villers, Arnauld
    Hugosson, Jonas
    Moore, Caroline M.
    EUROPEAN UROLOGY, 2015, 67 (04) : 627 - 636